Results 141 to 150 of about 1,973 (178)

Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease

Drugs, 2014
Sevelamer carbonate (Renvela(®)), a buffered form of sevelamer hydrochloride (Renagel(®)), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do ...
Caroline M Perry, Perry Caroline M, Plosker Greg L   +2 more
exaly   +3 more sources

Sevelamer carbonate in the management of hyperphosphatemia

Therapy, 2008
Sevelamer carbonate appears to be a promising new agent in the control of serum phosphorus levels in subjects with chronic kidney disease. It contains the same active moiety as sevelamer hydrochloride, but has carbonate instead of chloride as the counterion.
L Kooienga, R Moore
openaire   +1 more source

Sevelamer Carbonate Markedly Reduces Levothyroxine Absorption

Endocrine‚ Metabolic & Immune Disorders-Drug Targets, 2014
We report the case of a young woman affected by hypothyroidism due to Hashimoto's thyroiditis, previously well compensated with a full replacement therapy (150 mcg/day of levothyroxine), presenting a clinical picture of myxedema, with a TSH=650 mU/L. Two years earlier she had started a dialysis treatment because of a chronic renal failure and had been ...
Iovino M, Iovine N, Petrosino A, Giagulli VA, Licchelli B, GUASTAMACCHIA, Edoardo, TRIGGIANI, Vincenzo   +6 more
openaire   +2 more sources

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis

Clinical Nephrology, 2007
Sevelamer carbonate is an anion exchange resin with the same polymeric structure as sevelamer hydrochloride in which carbonate replaces chloride as the anion. The study investigated the effects of sevelamer carbonate and sevelamer hydrochloride on serum phosphorus, lipids and bicarbonate levels in hemodialysis patients.This was a double-blind ...
J, Delmez, G, Block, J, Robertson, S, Chasan-Taber, A, Blair, M, Dillon, A J, Bleyer   +6 more
openaire   +2 more sources

Does Concomitant Administration of Sevelamer and Calcium Carbonate Modify the Control of Phosphatemia?

Therapeutic Apheresis and Dialysis, 2010
AbstractThere is no guideline regarding the concomitant or distant administration of sevelamer and calcium carbonate. Our aim was to determine whether serum phosphate varied when sevelamer and calcium carbonate were administered concomitantly in comparison to administration at separate meals. Fourteen chronic hemodialysis patients were enrolled in this
Georges Ouellet, Louis-Georges Ste-Marie, Louise Roy   +2 more
exaly   +3 more sources

Effects of Calcium Carbonate, Sevelamer Hydrochloride or Pantoprazole on the Pharmacokinetics of Cinacalcet

Clinical Drug Investigation, 2014
Secondary hyperparathyroidism is a common consequence of chronic kidney disease. Cinacalcet (Sensipar(®)) is often prescribed in combination to reduce elevated levels of parathyroid hormone, calcium and phosphorus. The objective of this study was to assess the effects of concomitantly administered therapies of calcium carbonate (CaCO(3); TUMS ...
Desmond, Padhi, Robert, Harris, John T, Sullivan   +2 more
openaire   +2 more sources

Buffering Effects of Calcium Carbonate as Clarified by Sevelamer Hydrochloride Monotherapy

Therapeutic Apheresis and Dialysis, 2008
Abstract:  This study was undertaken to examine the necessity of taking into account the acid–base balance to ensure safe switching from calcium carbonate to sevelamer hydrochloride in hemodialysis patients. Forty‐two hemodialysis patients were divided into two groups: the sevelamer hydrochloride therapy group (n = 18; “monotherapy group”) and the ...
Toshio, Akatsuka, Toshio, Mochizuki, Takao, Koike   +2 more
openaire   +2 more sources

Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment

Therapeutic Apheresis and Dialysis, 2015
AbstractHyperphosphatemia is common in patients with chronic renal failure. Phosphate binders are associated with gastric intolerance, representing the main reason of drug discontinuation. The aim of this study was to compare the effects in vitro and in vivo of sevelamer hydrochloride (SH), sevelamer carbonate (SC) and lanthanum carbonate (LC) on ...
COPPOLINO, GIUSEPPE, LUCISANO, SILVIA, Rivoli, Laura, Fuiano, Giorgio, VILLARI, Antonino Gaet., VILLARI, IOLE, LEONELLO, Grazia, LACQUANITI, ANTONIO, SANTORO, Domenico, BUEMI, Michele   +9 more
openaire   +3 more sources

Survival in end stage renal disease: calcium carbonate vs. sevelamer

Journal of Clinical Pharmacy and Therapeutics, 2007
There is concern regarding long-term excess calcium intake in end-stage renal disease populations. Because calcium carbonate is an over-the-counter (OTC) medication, few studies have been able to track its use. The Veterans Health Administration (VA) tracks national pharmacy data for both OTC and prescription drugs.
A M, Borzecki, A, Lee, S W, Wang, L, Brenner, L E, Kazis   +4 more
openaire   +2 more sources

COMPARISON OF SEVELAMER AND CALCIUM CARBONATE ON ENDOTHELIAL FUNCTION AND INFLAMMATION IN PATIENTS ON PERITONEAL DIALYSIS

Journal of Renal Care, 2013
SUMMARYBackgroundHyperphosphataemia is a known independent risk factor for cardiovascular mortality. The objective of the study was to compare the effects of two phosphate binders, sevelamer carbonate and calcium carbonate on endothelial function (EF) and inflammation in patients on peritoneal dialysis (PD) with Type 2 diabetes mellitus (T2DM ...
Tetyana L Vasylyeva
exaly   +3 more sources